The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) hit a new 52-week low and has $3.81 target or 11.00% below today’s $4.28 share price. The 7 months bearish chart indicates high risk for the $169.08 million company. The 1-year low was reported on Nov, 14 by Barchart.com. If the $3.81 price target is reached, the company will be worth $18.60 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 23.60 million shares traded hands or 1729.46% up from the average. Dynavax Technologies Corporation (NASDAQ:DVAX) has declined 43.47% since April 12, 2016 and is downtrending. It has underperformed by 48.45% the S&P500.
Dynavax Technologies Corporation (NASDAQ:DVAX) Ratings Coverage
Out of 2 analysts covering Dynavax Technologies (NASDAQ:DVAX), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Dynavax Technologies has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. On Wednesday, April 27 the stock rating was downgraded by JP Morgan to “Neutral”. The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) earned “Hold” rating by Zacks on Wednesday, August 12. The stock has “Outperform” rating given by RBC Capital Markets on Monday, November 30. The firm has “Sector Perform” rating by RBC Capital Markets given on Thursday, April 28.
According to Zacks Investment Research, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.”
Insitutional Activity: The institutional sentiment decreased to 1.02 in Q2 2016. Its down 0.04, from 1.06 in 2016Q1. The ratio dropped, as 18 funds sold all Dynavax Technologies Corporation shares owned while 34 reduced positions. 10 funds bought stakes while 43 increased positions. They now own 31.67 million shares or 4.27% less from 33.08 million shares in 2016Q1.
Reilly Fincl Advisors Ltd Liability Corp accumulated 30 shares or 0% of the stock. Polar Capital Llp has 379,932 shares for 0.1% of their US portfolio. Ubs Asset Americas Inc last reported 0.01% of its portfolio in the stock. Wells Fargo Comm Mn has invested 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Northern Tru has 0% invested in the company for 468,166 shares. The New Jersey-based Sabby Management Ltd Co has invested 0.22% in Dynavax Technologies Corporation (NASDAQ:DVAX). Blair William & Il last reported 0.04% of its portfolio in the stock. Howard Hughes Med Institute holds 21,355 shares or 0.1% of its portfolio. Claar Advisors Ltd Liability last reported 0.91% of its portfolio in the stock. Allianz Asset Management Ag owns 117,492 shares or 0% of their US portfolio. Royal Retail Bank Of Canada has 0% invested in the company for 19,471 shares. Perceptive Advisors Lc last reported 0% of its portfolio in the stock. Earnest Prtn Limited Company, a Georgia-based fund reported 850 shares. Credit Suisse Ag has 33,597 shares for 0% of their US portfolio. Blackrock Japan, a Japan-based fund reported 2,875 shares.
Insider Transactions: Since May 20, 2016, the stock had 1 buying transaction, and 0 sales for $42,820 net activity. Gray Eddie had bought 2,750 shares worth $42,820.
Another recent and important Dynavax Technologies Corporation (NASDAQ:DVAX) news was published by 247Wallst.com which published an article titled: “Why Dynavax Shares Are in Freefall” on November 14, 2016.
DVAX Company Profile
Dynavax Technologies Corporation (Dynavax), incorporated on November 6, 2000, is a clinical-stage biopharmaceutical company. The Firm uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. The Company’s development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). The Company’s lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. The Company’s SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. The Company’s advanced inflammatory disease candidate is AZD1419. The Company’s pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.